Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT, 06510, USA.
Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
Br J Cancer. 2023 Apr;128(8):1439-1451. doi: 10.1038/s41416-023-02149-6. Epub 2023 Jan 26.
Colorectal cancer (CRC) is the third leading cause of cancer deaths worldwide and is characterised by frequently mutated genes, such as APC, TP53, KRAS and BRAF. The current treatment options of chemotherapy, radiation therapy and surgery are met with challenges such as cancer recurrence, drug resistance, and overt toxicity. CRC therapies exert their efficacy against cancer cells by activating biological pathways that contribute to various forms of regulated cell death (RCD). In 2012, ferroptosis was discovered as an iron-dependent and lipid peroxide-driven form of RCD. Recent studies suggest that therapies which target ferroptosis are promising treatment strategies for CRC. However, a greater understanding of the mechanisms of ferroptosis initiation, propagation, and resistance in CRC is needed. This review provides an overview of recent research in ferroptosis and its potential role as a therapeutic target in CRC. We also propose future research directions that could help to enhance our understanding of ferroptosis in CRC.
结直肠癌（CRC）是全球癌症死亡的第三大主要原因，其特征是经常发生基因突变，如 APC、TP53、KRAS 和 BRAF。目前的治疗选择包括化疗、放疗和手术，但面临着癌症复发、耐药性和明显毒性等挑战。CRC 治疗通过激活有助于各种形式的受调控细胞死亡（RCD）的生物途径来发挥对癌细胞的疗效。2012 年，铁死亡被发现是一种依赖铁和脂质过氧化物驱动的 RCD 形式。最近的研究表明，针对铁死亡的治疗方法是 CRC 有前途的治疗策略。然而，需要更深入地了解 CRC 中铁死亡的起始、传播和耐药机制。本综述概述了铁死亡的最新研究及其在 CRC 中作为治疗靶点的潜在作用。我们还提出了未来的研究方向，这可能有助于我们加深对 CRC 中铁死亡的理解。
